The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
about
New agents for the treatment of drug-resistant Mycobacterium tuberculosisCurrent and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challengeBacterial lipids: metabolism and membrane homeostasisAntimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and futureRational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the Staphylococcus aureus FabI Enzyme–Product ComplexStaphylococcus aureus FabI: Inhibition, Substrate Recognition, and Potential Implications for In Vivo EssentialityRational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase InhibitorResistance Mechanisms and the Future of Bacterial Enoyl-Acyl Carrier Protein Reductase (FabI) AntibioticsGonorrhea - an evolving disease of the new millennium.Investigational antimicrobial agents of 2013.Radiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureusMeleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.FabH mutations confer resistance to FabF-directed antibiotics in Staphylococcus aureusHow bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics.Mutations upstream of fabI in triclosan resistant Staphylococcus aureus strains are associated with elevated fabI gene expression.Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252.A Pathogen-Selective Antibiotic Minimizes Disturbance to the Microbiome.Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.Antimicrobial Resistance Expressed by Neisseria gonorrhoeae: A Major Global Public Health Problem in the 21st Century.Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials.Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).Structural characterisation of the fatty acid biosynthesis enzyme FabF from the pathogen Listeria monocytogenes.Recent advances in inhibitors of bacterial fatty acid synthesis type II (FASII) system enzymes as potential antibacterial agents.Antibiotic resistance in Staphylococcus aureus. Current status and future prospects.Enoyl acyl carrier protein reductase inhibitors: an updated patent review (2011 - 2015).Bacterial fatty acid metabolism in modern antibiotic discovery.Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development.Exogenous fatty acid metabolism in bacteria.Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.Clinical Relevance of Type II Fatty Acid Synthesis Bypass in Staphylococcus aureus.Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics.Dissemination of Novel Antimicrobial Resistance Mechanisms through the Insertion Sequence Mediated Spread of Metabolic Genes.Staphylococcus aureus utilizes host-derived lipoprotein particles as sources of exogenous fatty acids.
P2860
Q26751463-E206D02D-F34C-4346-BD10-768F7536C078Q26796265-B5FCB986-445B-42A2-BEEC-86AD3D62082AQ26829512-A0A33EB2-4094-43E0-B94D-D9D3EB5037DCQ26862597-724C6CEF-BD14-4ADA-8FE7-BE3CD3EFD673Q27678258-6B62270D-616A-49D0-86F5-8C29D963615CQ27679034-E7519A48-0139-44AA-A585-401A96777C73Q27683440-373B2D5F-DBA5-44ED-B319-826D7EB2A25CQ28069943-5D290C6F-3349-45BF-B90C-847018B082A7Q30235031-5B69AED9-4E4C-4A7C-9560-7D7A58C83A2EQ34375204-0AC94804-F7BE-4B41-B789-22128995EC01Q34622399-60568506-F31F-4718-A113-63912F950A48Q35060154-A6A86815-0592-45C8-9958-9493044F4163Q35105888-D7B5FACB-D4B3-4E76-A1C2-7FF89601C4B4Q35172866-F1C3A048-9952-4462-B2FC-1E35AEE70371Q35618052-451CAF25-4BD2-4617-AD6C-3194F37AF37BQ36785831-5B61F43E-4244-4555-A266-18E28200D507Q37023140-226EEBA6-F56C-49FC-BE34-A645C34D4ABFQ37030173-E9A96F30-CEFB-4605-9CD2-5E291C7EA05CQ37036002-5CD14CAA-701F-4B6E-A65A-02455F376951Q37329885-EC09743D-8B94-4EE4-8AC0-C65E723F95EBQ37404976-5C84D995-2FBD-45C7-8B0D-885EFC14FBBCQ37550416-F9873B96-BF80-4737-B33D-AB317D2D0ACCQ38124842-B468C16A-D5F8-4CCB-BFE1-3853DDA645A9Q38728885-7A80E661-06EA-4C53-A476-018A987EC6DFQ38892242-62AA761B-E8E3-431B-8F63-72BBF948993AQ38964523-FF1E1916-C072-491B-868A-6012998F4294Q39275601-EAE9BB8B-28DB-49FF-AB29-B0A26E89E364Q39408643-7634B001-B30B-43AF-899B-2C0758F07B08Q40322173-E9F34701-D24D-4F8B-B1C2-F62BDFF6E43DQ40334483-7133B871-352E-451D-93EE-0E55DE4804B1Q41855966-1B1DC857-5423-4510-9FFF-C5F86B0A002CQ42137262-6512D373-699C-4B9E-8C0A-A47189D3446EQ52629550-92C5F0ED-577B-4363-A64A-149289A412E7
P2860
The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
@ast
The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
@en
type
label
The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
@ast
The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
@en
prefLabel
The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
@ast
The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
@en
P2093
P2860
P356
P1476
The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
@en
P2093
C Soulama-Mouze
Ian Morrissey
Kirsty Maher
L Prouvensier
M Saccomani
P2860
P304
P356
10.1128/AAC.01248-10
P407
P577
2011-08-08T00:00:00Z